Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Lowered by StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other research analysts also recently issued reports on AUPH. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH traded down $0.32 on Friday, hitting $9.37. 1,277,609 shares of the company’s stock traded hands, compared to its average volume of 1,607,037. The firm’s 50-day moving average price is $7.99 and its two-hundred day moving average price is $6.71. The firm has a market capitalization of $1.34 billion, a PE ratio of -62.46 and a beta of 1.41. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.67.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now directly owns 13,356 shares in the company, valued at $112,591.08. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AUPH. FMR LLC raised its stake in shares of Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after buying an additional 3,919 shares during the period. The Manufacturers Life Insurance Company raised its position in Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock worth $301,000 after acquiring an additional 4,808 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Aurinia Pharmaceuticals by 15.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 5,079 shares in the last quarter. Banque Cantonale Vaudoise grew its position in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 5,410 shares during the period. Finally, Handelsbanken Fonder AB increased its stake in shares of Aurinia Pharmaceuticals by 13.2% during the third quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock worth $445,000 after purchasing an additional 7,100 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.